Work

Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study

Year: 2023

Type: article

Study design: Clinical Trial

Source: The Lancet Haematology

DOI: 10.1016/s2352-3026(22)00403-3

Authors: Guillermo Garcia-Manero, Aaron D Goldberg, Eric S Winer, Jessica K Altman, Amir T Fathi, Olatoyosi Odenike, Gail J Roboz, Kendra Sweet, Crystal Miller, Anders Wennborg, Denice K Hickman, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Jeffrey Lancet, Rami Komrokji, Eyal C Attar, David A Sallman

Institutions: The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Massachusetts General Hospital, University of Chicago, University of Chicago Medical Center, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Moffitt Cancer Center, Aprea Therapeutics, Inc. (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4361026824

FWCI: 17.34

Cites: 31

Cited by: 91

Related to: 10